Search results
Order by most recent / most popular / relevance
Results: 1-10 of 196
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 1 2013
The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the
Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 6 2013
In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a
Court of Appeal permits sampling of Apotex’s products
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
The Court of Appeal is permitting several innovator pharmaceutical companies to obtain samples of Apotex’s drug products for destructive testing
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Health Canada has released a Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of
NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
Health Canada has opened a consultation on the International Conference on Harmonisation of Technical Requirements for the Registration of
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 6 2013
The PMPRB has announced a Monitoring and Evaluation Plan for the Major Changes in the Guidelines. CIPO has announced a new PCT-Patent Prosecution
Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits
Court dismisses NOC proceeding for mootness when NOA withdrawn
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to
Current Search
- Workarea - Healthcare
- Author - Beverley Moore